Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML
Status:
Not yet recruiting
Trial end date:
2028-10-20
Target enrollment:
Participant gender:
Summary
This project is a prospective, multicenter, randomized controlled clinical study. The
subjects were refractory / relapsed AML patients aged ≤ 60 years diagnosed by bone marrow
cell morphology, immunology, genetics and therapeutic efficacy evaluation. The classical Bu /
Cy scheme or MCBC scheme was used for pretreatment. The primary endpoint of the study was the
3-year recurrence-free survival rate after allogeneic hematopoietic stem cell
transplantation, and the secondary endpoints were 3-year overall survival rate, recurrence
rate, treatment-related mortality, and pretreatment-related toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China